CA-VELODYNE/SEOUL-ROBO
Velodyne Lidar, Inc. (Booth #6091), in collaboration with Seoul Robotics , will demonstrate how its smart, powerful lidar solutions advance automation and safety in manufacturing and supply chain solutions at MODEX 2020 in Atlanta, March 9-12. Velodyne will highlight lidar sensors that can be used in robotics, automated guided vehicles (AGV), forklifts and security applications. Velodyne lidar solutions can improve industrial automation, materials handling, yard management and distribution center operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200227005194/en/
At its MODEX booth, Velodyne will showcase the Puck 32MR™, a lidar sensor which produces a data-rich image with the ability to detect low reflectivity objects at a range of 120 meters. The sensor is optimized for outstanding indoor/outdoor performance, operating in a variety of light conditions. By combining high-resolution 3D perception with a broad vertical field of view, the Puck 32MR accurately detects crosswalks, curbs and obstacles in warehouse aisles for safe and efficient navigation in roadway, commercial and industrial settings.
Velodyne will also highlight the Velarray™, a powerful sensor solution to greatly improve automated safety. Its small, embeddable form factor enables the sensor to be seamlessly integrated into a variety of industrial and robotics equipment. The Velarray produces a robust directional image, day or night.
“As the demands for supply chain efficiency and safety increase and evolve, lidar technology is helping companies vastly improve manufacturing and logistics performance,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “Supply chain systems need to continue to become smarter and safer, more efficient and further automated. To address these requirements, companies are turning to lidar to play a key role in enabling the next generation of manufacturing and supply chain solutions.”
At Velodyne’s MODEX booth, Seoul Robotics will demonstrate the benefits and applications of Level 5 Control Tower solution, powered by its proprietary AI engine, SENSR™, which is optimized and available commercially to process Velodyne’s rich and reliable 3D data. Seoul Robotics uses artificial intelligence (AI) for detection, counting, classification and tracking of objects in real time. It can accurately track the location, coordinates, speed and direction of objects and predict their path, such as vehicles and people at a distribution center or manufacturing and logistics operation.
“As vehicles and material handling equipment are increasingly automated in logistics yards and distribution centers, industry must develop and deploy in parallel a robust and safe operating environment. This will resolve well-known challenges with trucks and equipment, such as blind spots and occlusion, in order to successfully realize the promised efficiency and economy,” said David Han, Seoul Robotics’ Managing Director of North America & Global Automotive. “Level 5 Control Tower equipped with Velodyne lidar enables exactly that – a robust and cost-effective infrastructure-based perception solution that monitors and guides the movement of automated and conventional vehicles within the entire yard – efficiently and safely.”
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
About Seoul Robotics
Seoul Robotics is a 3D Perception AI company that specializes in Lidar perception solutions, powered by its proprietary and versatile SENSR™ perception platform suite. Based in Seoul, South Korea with U.S. branch office in Ann Arbor, Michigan, Seoul Robotics is developing customers and projects in the ADAS/AV, Security, Smart Factory and Logistics, and Robotics markets worldwide. Seoul Robotics works collaboratively with partners across the value chain – including Lidar manufacturers, global automotive and industrial OEM’s and Tier 1 & 2 suppliers, engineering companies, and government customers – to advance perception solutions that make robots intelligent. Visit www.seoulrobotics.org for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005194/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
